Uncategorized

Aclipse Therapeutics and its subsidiary Aclipse One Inc (“Aclipse” or “the Company”), an innovative biopharmaceutical company, today announced that the Company has received a therapeutic development award of $1.475 million from the Congressionally Directed Medical Research Programs (CDMRP) at the United States Department of Defense’s (DOD) U.S. Army Medical Research and Development Command (USAMRDC), as part of its FY21 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award. The award will fund the research by the Company and its collaborator, the Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield in the United Kingdom (UK) entitled, “Development of M102 to Investigational New Drug (IND) Stage for Initiation of Phase I Clinical Trials for Treating Amyotrophic Lateral Sclerosis (ALS).”

CEOCFO Magazine has interviewed Aclipse Therapeutics CEO Raymond Houck. Mr. Houck has introduced the background of the company and our lead drug product M102. He has also described the target pathomechanisms of M102 and its precision medicine approach to ALS and CNS diseases.

Funding Supports Aclipse Therapeutics’ and Sheffield Institute of Translational Neuroscience’s Development of M102 in Amyotrophic Lateral Sclerosis 

Radnor, PA — January 26, 2021 – Aclipse Therapeutics (“Aclipse” or “the Company”), a private biopharmaceutical company, today announced that the Company and its collaborator, The Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield in the United Kingdom (UK), were awarded a drug development research grant of £1.6 million (approximately US $2.2 million) from the UK’s Medical Research Council (MRC), one of the largest funders of medical research worldwide, to support the translational development of M102. M102 is Aclipse’s drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also referred to as motor neuron disease (MND) or Lou Gehrig’s disease. 

Aclipse Therapeutics was awarded an AUD 1 million (approximately US $720,000) drug development research grant from FightMND, the largest independent funder of ALS research in Australia. The grant will support the translational development of M102, a drug candidate for the treatment of ALS. M102 showed promise to stop and reverse ALS disease progression, as evidenced by data in preclinical models. Currently, there is no cure for ALS and no effective treatments to halt or reverse the progression of this devastating disease.

Aclipse Therapeutics has successfully conducted the US FDA pre-IND meeting for M102. The FDA has reviewed the M102 preclinical data package and confirmed the necessary preclinical studies for M102 to initiate its first-in-human studies. The agency has also provided valuable guidance to support the clinical development of M102.